公开(公告)号：KR20180067584A

公开(公告)日：2018-06-20

申请号：KR20187012886

申请日：2016-06-30

Applicant: ACEA THERAPEUTICS INC

Inventor： MAO LONG ,  LIU JIA ,  CHEN YILE ,  HUA YUNING ,  DAI KONGEN ,  BAO YIMEI ,  WENG BOJIE ,  MO XIAOPENG ,  WU JIAN ,  XU XIAO ,  XU WANHONG ,  WANG XIAOBO

IPC: A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  C07D487/04

CPC classification number: A61K31/52 ,  C07D487/04

Abstract: 본발명은증식질환및 키나아제 (EGFR (HER을포함), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC, 및 TXK와같은것들이나이에한정되지는않음)의조절장애와관련된다른질환의치료에효과적인특정한피롤로피리미딘화합물을제조하는방법. 상기화합물들의개개의경로, 염, 다형체및 비정질형태, 상기화합물을제조하는합성중간체, 및상기화합물을포함하는약학조성물및 이러한조성물들의제조방법에관한것이다.

公开(公告)号：TW201841641A

公开(公告)日：2018-12-01

申请号：TW107111765

申请日：2018-04-03

Applicant: 美商艾森醫藥有限公司 ,  ACEA THERAPEUTICS, INC.

Inventor： 毛 龍 ,  MAO, LONG ,  劉 佳 ,  LIU, JIA ,  陳以樂 ,  CHEN, YILE ,  華宇寧 ,  HUA, YUNING ,  代孔恩 ,  DAI, KONGEN ,  包益梅 ,  BAO, YIMEI ,  翁波杰 ,  WENG, BOJIE ,  莫小鵬 ,  MO, XIAOPENG ,  吳健 ,  WU, JIAN ,  徐 曉 ,  XU, XIAO ,  徐萬紅 ,  XU, WANHONG ,  王 小波 ,  WANG, XIAOBO

IPC: A61K31/519 ,  A61K47/10 ,  A61K47/12 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K9/00 ,  A61K9/20 ,  C07D487/04

Abstract: 本發明係關於製造某些吡咯并嘧啶衍生物之方法，該等衍生物適用於治療增殖病症及與激酶(諸如(但不限於) EGFR (包括HER)、Alk、PDGFR、BLK、BMX/ETK、BTK、FLT3(D835Y)、ITK、JAK1、JAK2、JAK3、TEC及TXK)及/或對應路徑之調節異常相關之其他疾病；係關於該等化合物之鹽、多晶型物及非晶型式，用於製備該等化合物之合成中間物，及包含該等化合物之醫藥組合物以及製造此類組合物的方法。

Abstract in simplified Chinese: 本发明系关于制造某些吡咯并嘧啶衍生物之方法，该等衍生物适用于治疗增殖病症及与激酶(诸如(但不限于) EGFR (包括HER)、Alk、PDGFR、BLK、BMX/ETK、BTK、FLT3(D835Y)、ITK、JAK1、JAK2、JAK3、TEC及TXK)及/或对应路径之调节异常相关之其他疾病；系关于该等化合物之盐、多晶型物及非晶型式，用于制备该等化合物之合成中间物，及包含该等化合物之医药组合物以及制造此类组合物的方法。

公开(公告)号：US20230026438A1

公开(公告)日：2023-01-26

申请号：US17830185

申请日：2022-06-01

Applicant: ACEA Therapeutics, Inc.

Inventor： Long Mao ,  Xiao Xu ,  Namir Shaabani ,  Can Jin

IPC: C07D207/26 ,  C07D403/12 ,  C07D413/14 ,  C07D401/12 ,  C07D403/14 ,  C07D401/14 ,  C07D207/416

Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

公开(公告)号：US20250136576A1

公开(公告)日：2025-05-01

申请号：US18578240

申请日：2022-07-12

Applicant: ACEA Therapeutics, Inc. ,  Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Inventor： Long Mao ,  Wei Tang ,  Xiaoying Zhang ,  Rongda Xu ,  Yile Chen ,  Xiao Xu ,  Changxu Xu

IPC: C07D401/12 ,  C07D471/04 ,  C07D491/048

Abstract: The present disclosure relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods comprising a compound of any one of Formulas (I), (II), (III), and (IV) as further described herein. The compounds are inhibitors of protein kinases associated with cancers, and are thus useful for the treatment and/or prevention of a tumor or cancer.

公开(公告)号：US11753373B2

公开(公告)日：2023-09-12

申请号：US17830185

申请日：2022-06-01

Applicant: ACEA Therapeutics, Inc.

Inventor： Long Mao ,  Xiao Xu ,  Namir Shaabani ,  Can Jin

IPC: C07D401/12 ,  C07D403/12 ,  C07D207/26 ,  C07D207/416 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

CPC classification number: C07D207/26 ,  C07D207/416 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)




and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

公开(公告)号：US20210300931A1

公开(公告)日：2021-09-30

申请号：US16500384

申请日：2017-04-07

Applicant: ACEA Therapeutics, Inc. ,  Hangzhou ACEA Pharmaceutical Research Co., Ltd. ,  Zhejiang ACEA Pharmaceuticals Co., Ltd.

Inventor： Long MAO ,  Jia LIU ,  Yile CHEN ,  Yuning HUA ,  Kongen DAI ,  Yimei BAO ,  Bojie WENG ,  Xi-aopeng MO ,  Jian WU ,  Xiao XU ,  Wanhong XU ,  Xiaobo WANG

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/00

Abstract: Disclosed methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC AND TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.

公开(公告)号：US11007197B2

公开(公告)日：2021-05-18

申请号：US16587110

申请日：2019-09-30

Applicant: ACEA Therapeutics, Inc.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/519 ,  C07D487/04 ,  A61K45/06

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US10533011B2

公开(公告)日：2020-01-14

申请号：US15766736

申请日：2016-06-30

Applicant: ACEA THERAPEUTICS, INC.

Inventor： Long Mao ,  Jia Liu ,  Yile Chen ,  Yuning Hua ,  Kongen Dai ,  Yimei Bao ,  Bojie Weng ,  Xiaopeng Mo ,  Jian Wu ,  Xiao Xu ,  Wanhong Xu ,  Xiaobo Wang

IPC: C07D487/04 ,  A61K9/48 ,  A61K9/20

Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.

公开(公告)号：US11612602B2

公开(公告)日：2023-03-28

申请号：US17001147

申请日：2020-08-24

Applicant: ACEA Therapeutics, Inc.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/519 ,  C07D403/12 ,  A61P35/00 ,  A61K31/52 ,  C07D473/32 ,  A61K31/506 ,  C07D487/04 ,  C07D401/14 ,  C07D473/34 ,  A61K45/06 ,  C07D239/48 ,  C07D473/24 ,  C07D239/46 ,  C07D473/40 ,  C07D239/42 ,  C07D487/02 ,  C07D473/16 ,  C07D239/47 ,  C07D401/12

Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US11498922B2

公开(公告)日：2022-11-15

申请号：US16500384

申请日：2017-04-07

Applicant: ACEA Therapeutics, Inc. ,  Hangzhou ACEA Pharmaceutical Research Co., Ltd. ,  Zhejiang ACEA Pharmaceuticals Co., Ltd

Inventor： Long Mao ,  Jia Liu ,  Yile Chen ,  Yuning Hua ,  Kongen Dai ,  Yimei Bao ,  Bojie Weng ,  Xi-aopeng Mo ,  Jian Wu ,  Xiao Xu ,  Wanhong Xu ,  Xiaobo Wang

IPC: A61K31/519 ,  C07D487/04 ,  A61K9/00 ,  A61K9/20

Abstract: The present invention relates to methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.